Indium (In-111)klorid Curium Netherlands

Indium-111 chloride, the active ingredient in Indium (In-111)klorid Curium Netherlands, is a radiopharmaceutical presented as a radiopharmaceutical for intravenous use. It is employed as a diagnostic imaging agent that emits detectable gamma radiation for nuclear medicine procedures. GNH USA supplies Indium (In-111)klorid Curium Netherlands as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Indium-111 chloride is used in nuclear medicine for imaging applications that require targeted gamma‑ray emission. - Lymphoscintigraphy: visualizes lymphatic drainage pathways and sentinel lymph nodes. - Infection imaging: localizes sites of infection or inflammation by labeling leukocytes. - Tumor targeting: assists in identifying tumor sites when bound to specific antibodies or peptides. - Bone marrow imaging: evaluates marrow activity and distribution. - Cardiac imaging: assesses myocardial perfusion in selected protocols.

Indium-111 chloride may cause reactions related to its radioactive nature and intravenous administration.

Common Side Effects: - Injection site pain: mild discomfort at the site of administration. - Nausea: transient feeling of queasiness. - Transient flushing: brief warmth or redness. - Mild headache: short‑lasting headache. - Low‑grade fever: temporary elevation of body temperature.

Serious or Rare Side Effects: - Allergic reaction: rash, urticaria, or anaphylaxis. - Radiation‑induced tissue injury: localized damage at high cumulative doses. - Hematologic changes: temporary reduction in blood cell counts. - Renal impairment: rare impact on kidney function. - Severe hypotension: sudden drop in blood pressure post‑injection.

When handling Indium-111 chloride, follow standard radiopharmacy safety protocols. - Radiation protection: use shielding and limit exposure time. - Patient assessment: evaluate for known hypersensitivity to radiopharmaceuticals. - Pregnancy consideration: avoid use unless benefits outweigh potential fetal radiation risk. - Breastfeeding: discontinue breastfeeding if administered to lactating patients. - Renal function: assess kidney function before administration. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Indium-111 chloride may interact with substances that affect radiation distribution or clearance.

Major Interactions (Avoid): - Chelating agents: can bind the isotope and alter biodistribution. - High‑dose steroids: may reduce inflammatory cell labeling.

Moderate Interactions (Monitor Closely): - Anticoagulants: may increase risk of bleeding at injection site. - Renal‑clearing drugs: could affect renal excretion of the radiotracer. - Contrast agents: may interfere with imaging interpretation. - Other radiopharmaceuticals: cumulative radiation dose considerations. - Immunosuppressants: may modify immune cell labeling efficiency.